<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Matucci-Cerinic, Marco</style></author><author><style face="normal" font="default" size="100%">Luqmani, Raashid</style></author><author><style face="normal" font="default" size="100%">Yazici, Hasan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EULAR Recommendations for the Management of Rheumatic Diseases: 2007 Updates</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-33</style></pages><abstract><style  face="normal" font="default" size="100%">The European League Against Rheumatism Standing Committee on International Clinical Studies, including Therapeutic Trials regularly establishes and publishes evidence-based recommendations for the management of rheumatic disorders, as well as recommendation for conducting/reporting clinical trials. Each of these recommendations is developed by a combined approach involving both review of available research evidence and expert consensus; incorporation of a third type of evidence – patient opinion – is now undertaken for management recommendations. This article discusses several new and revised recommendations.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>